Conversations AI for Depression Care: Hearing Patient Voices in MDD
Official title: Evaluating Conversational Artificial Intelligence for Depression Management
Run by George Mason University · NCT07105397 · Data updated 2026-11-12
A home-based conversational AI intake is tested to see if it changes how patients with major depressive disorder feel about the empathy they receive compared with usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | George Mason University Academic / other |
| Locations | 1 site (Fairfax, Virginia) |
| Status | Recruiting |
| Started | July 22, 2026 |
| Main results expected | April 15, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT07105397 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-85 with moderate to severe MDD, not in active suicidal crisis, fluent in English, and residing in the United States.
✕Probably not a fit
Participants who do not perceive changes in empathy or who have interactions not affected by the AI intake may see no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares a conversational AI intake with standard clinical intake in adults with moderate to severe major depressive disorder. Participants complete the AI intake at home and then experience usual care, with the order randomized to minimize sequence effects. Each participant serves as their own control, and outcomes focus on perceived empathy during clinical interactions over four months. The approach uses an advanced AI system guided by a structured knowledge network and a novel patient-simulator framework to ensure relevant, coherent conversations. The trial addresses safety, reliability, and the potential to streamline antidepressant decision-making in real-world settings.
Why it matters
Potential benefit: If successful, the AI intake could enhance patient-perceived empathy and streamline initial clinical encounters.
How similar studies have gone: Prior work with conversational AI in healthcare shows potential for improved patient experience, but results vary and rigorous clinical testing is ongoing.
Who can join: the full rules
Show full inclusion / exclusion criteria
1. Participant is between 18 to 85 years old. 2. Participant has been, or are likely to be, diagnosed with moderate to severe Major Depressive Disorder without signs of bipolar depression. 3. Participant is not in active suicidal crisis and do not face imminent risk of suicide within the next 3 hours. 4. Participant is not pregnant or seeking to be pregnant. 5. Participant able to communicate in English on the Internet. 6. Participant must reside in the United States. 7. Participant has access to a mental health clinician, or the participant is willing to see study clinicians to help review the advice and medication adjustments recommended by the AI Intake System to the participant. 8. If the participant is seeing study clinicians, the participant must reside in a state where study clinicians are licensed. 9. Participant must be using a device (phone or computer) that is located in the United States.
Where it's running
-
George Mason University
Fairfax, Virginia, United States Recruiting
Study contacts
- Study coordinator: Farrokh Alemi, PhD
- Email: rapidai@gmu.edu
- Phone: 7579459484
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures
This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.
-
Temporally Interfering Electrical Stimulation for Major Depressive Disorder
This study tests whether noninvasive temporally interfering electrical stimulation can help people with major depressive disorder.
-
Affective Cognitive Training for mood disorders and their close relatives
A six-week program combining virtual reality and computer exercises tests whether affective cognitive training helps people with mood disorders and their unaffected first-degree relatives.
-
ALKS 7290 added to antidepressants for adults with major depression
This study tests whether ALKS 7290, taken with current antidepressants, helps adults with major depressive disorder.
-
French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls
This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.
-
EEG-Guided TMS for Adults With Depression
This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.